Navigation Links
Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH
Date:11/14/2011

cond product candidate, which consists of a subcutaneously administered formulation of the specific Factor IXa inhibitor, pegnivacogin, (a.k.a. RB006), paired with an IV bolus formulation of its complementary active control agent, anivamersen, (a.k.a. RB007).  REG2 is anticipated to provide a favorable therapeutic profile with a slow onset of action and duration of effect lasting several days, ideally suited for venous thrombosis indications.

"Presenting such positive REG1 and REG2 data to an audience of industry peers at AHA validates the potential of Regado's science and pipeline," said David J. Mazzo, PhD, President and CEO of Regado.  "The RADAR trial results further demonstrate REG1's ability to promote early arterial sheath removal after cardiac catheterization without increasing time to hemostasis.  We believe this data provides additional validation of REG1's favorable profile as the only truly reversible anticoagulant in development."

"REG2 has also demonstrated significant potential for application in venous thrombosis indications, which is a commentary on our strong pipeline," Dr. Mazzo continued.

About Regado Biosciences

Regado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent.  This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrom
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Regado Biosciences, Inc. to Present at the Sofinnova Japan Biopharma Partnering Conference in Tokyo, Japan
2. Regado Biosciences to Present at the Annual UBS Global Life Sciences Conference in New York City
3. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
4. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
5. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
6. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
7. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
8. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
9. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
10. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
11. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  A new analysis of Centers for Medicare ... data shows that 81 percent of seniors chose lower-cost ... discounts at certain pharmacies. The findings were released by ... are now the foundation of Medicare Part D," said ...
(Date:1/23/2015)... More than a third of reproductive-aged women enrolled in ... insurance, filled a prescription for an opioid pain medication each ... Morbidity and Mortality Weekly Report (MMWR). Opioids ... to severe pain.  They are also found in some prescription ...
(Date:1/23/2015)...  Pete Rose, baseball,s all-time hits leader, is the new spokesperson ... Ducere Pharma has announced. "Pete,s a Hall of ... him on board with Myoflex," said Ducere Pharma Chief Executive ... who is known across all generations. The passion and intensity ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3Pete Rose bets on Myoflex to relieve aches and pains 2
... the market leader in automated revenue integrity solutions, ... Regional Medical Center, a 235-bed non-profit medical center ... nation,s five star hospitals in community value, Kingman ... to the range of Craneware Revenue Integrity Solutions™ ...
... Mass., June 2, 2011 Cynosure, Inc. (NASDAQ: ... minimally invasive and non-invasive aesthetic applications, today announced that it ... 1:30 p.m. (ET) on Thursday, June 9 in New York ... CEO Michael Davin and Executive Vice President, Treasurer and CFO ...
Cached Medicine Technology:Kingman Adds Craneware Revenue Integrity Solution - InSight Denials® 2Kingman Adds Craneware Revenue Integrity Solution - InSight Denials® 3Kingman Adds Craneware Revenue Integrity Solution - InSight Denials® 4
(Date:1/22/2015)... January 22, 2015 Padre Murphy's and Owner ... of Pro Player Health Alliance (PPHA). The PPHA's ... in getting everyone, including NFL greats, treated for obstructive sleep ... leading groups supporting the cause in the valley. The most ...
(Date:1/22/2015)... January 22, 2015 Blue Cross and Blue ... who exemplify what it means to “Live Fearless.” ... people to share their stories about how they or someone ... inspired others by living in the moment. By telling these ...
(Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
(Date:1/22/2015)... January 22, 2015 Carinsurancesavings.biz has released a ... death and dismemberment insurance . , Purchasing an accidental ... be very advantageous. This type of rider provides benefits if ... can be considered a lesser form of life insurance. ...
(Date:1/22/2015)... Weddingshe.com has added many trendy Champagne wedding dresses ... in the past three years. Today, the business announces a ... to the sales manager of the company, this is on ... This point can be reflected on the discounted wedding dresses ...
Breaking Medicine News(10 mins):Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... Expansion ... CP,s Declared Uncertainty, ROCHESTER, Minn., Feb. 1 Mayo ... mitigation for,the city of Rochester as a condition of the ... (DM&E). The,proposed merger currently ignores the significant environmental impacts,created by ...
... Beaumont Technology,Usability Center will begin research on the ... study on tubing and catheter misconnection errors., ... Event Alert on the,potential dangers of tubing misconnections. ... of permanent loss of function were due to ...
... new ways to tackle certain diseases could be provided by ... to a Perspective article published today in the journal Nature ... microbes live symbiotically in the human gut. They play a ... inside the body. Different people have different types of gut ...
... but preventable, and urges better pediatric controls , , FRIDAY, ... unintended harm or suffering caused by health care -- ... new French research. , These IEs are sometimes serious ... Hospital in Marseille, France. , They looked at 388 ...
... Health,sponsors the Kaiser Permanente San Francisco Half Marathon & ... the Hemophilia Foundation of,Northern California, Support for Families of ... to take place on Feb. 3, this RRCA Western ... as one of the most scenic,in the country by ...
... and goodwill that,epitomise Christmas and the New Year. It is ... partying., This can be one of the worst times ... parties, neighbours, parties; it goes on and,on. Then comes January ... some the merriment of Christmas and the New Year masks ...
Cached Medicine News:Health News:Mayo Clinic Seeks Mitigation for Rochester as Condition of Canadian Pacific - DM&E Railroad Merger 2Health News:Mayo Clinic Seeks Mitigation for Rochester as Condition of Canadian Pacific - DM&E Railroad Merger 3Health News:Mayo Clinic Seeks Mitigation for Rochester as Condition of Canadian Pacific - DM&E Railroad Merger 4Health News:FDA Renews its Contract with Beaumont Technology Usability Center for Leadership of Patient Safety Project 2Health News:Targeting gut bugs could revolutionize future drugs, say researcher 2Health News:Unintended Errors Leave Many Newborns Vulnerable 2Health News:A Festive White Knuckle Ride? 2
... the MAMMOTOME® HH (Hand Held) ... procedure using ultrasound imaging for ... to locate breast abnormalities, you ... map the area you will ...
... SEAMGUARD® Staple Line Reinforcement Material is ... postoperative pulmonary air leaks and as ... This inert, biocompatible, ePTFE material requires ... easy to load and fire and ...
... Sepramesh Biosurgical Composite is designed for ... of a PPM mesh that has two ... mesh is coated with a layer of ... Biosurgery's Seprafilm® Adhesion Barrier). This coated side ...
... Hernia Repair Company, we recognize that there ... fibrous tissue in-growth between the prosthesis and ... mesh. Like all the products in Bards ... a clinically proven, versatile repair.,The Reconix Patch ...
Medicine Products: